Drugmakers Aim to Challenge Novo Nordisk and Eli Lilly in Obesity Market
As of June 2026, the global pharmaceutical sector is intensifying efforts to challenge the market dominance of Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) in the GLP-1 obesity ... Read More